Effects of kivia powder on Gut health in patients with occasional constipation: a randomized, double-blind, placebo-controlled study

Nutrition Journal

David W Bloom¹  Jay K Udani² 

[1] Medicus Research LLC, Agoura Hills, CA 91301, USA;Medical Director, Northridge Hospital Integrative Medicine Program, Northridge, CA 91325, USA

关键词: Zyactinase™;    Actinidin;    Kiwi Fruit;    Constipation;   

Others  :  806592
DOI  :  10.1186/1475-2891-12-78

 received in 2012-08-21, accepted in 2013-04-30,  发布年份 2013

【 摘 要 】

Objective

To evaluate the efficacy of Kivia powder on supporting overall gut health through the relief of the discomfort of occasional constipation.

Design

Randomized, double-blind, placebo-controlled, parallel-group trial.

Interventions

The investigational product for this study was Kivia powder (Vital Food Processors Ltd., Auckland, New Zealand), containing the active ingredient Zyactinase™, 5.5 g taken daily for four weeks.

Results

One hundred thirty-eight subjects reporting occasional constipation were screened and 87 were randomized to placebo (n = 44) and product (n = 43). Bowel movement frequency, as measured by both average daily spontaneous bowel movements (SBM) and complete spontaneous bowel movements (CSBM), were the same in both groups at baseline. There were significant increases in spontaneous bowel movements at week 1 (p = 0.001), week 2 (p = 0.001), week 3 (p = 0.000), and week 4 (p = 0.000) compared to baseline. SBM demonstrated significant differences between the treatment group and the placebo group at week 3 (p = 0.000), and week 4 (p = 0.020). The treatment group demonstrated a significantly higher rate of SBM at week 3 (p = 000) and from baseline to week 4 (p = 0.019). Significant increases in complete spontaneous bowel movements were observed at week 1 (p = 0.000), week 2 (p = 0.000), week 3 (p = 0.000), and week 4 (p = 0.000) compared to baseline. Moreover, CSBM was significantly higher for the treatment group compared to placebo at week 2 (p = 0.001). The change in average daily CSBM from baseline to week 2 was significantly higher in the treatment group than in the placebo group (p = 0.004).

Abdominal discomfort or pain demonstrated significant differences between groups at week 1 (p = 0.044) and week 3 (p = 0.026). Flatulence was significantly lower for active group compared to placebo at week 2 (p = 0.047) and week 3 (p = 0.023). The number of bowel movements associated with urgency was significantly lower in the treatment group compared to the placebo group at week 3 (p = 0.048). In addition, it was decreased from baseline to week 1 (p = 0.040) and from baseline to week 3 (p = 0.024) in the treatment group, while the placebo group did not report any reductions in bowel urgency. Bowel movements in the treatment arm were significantly smoother and softer by week 2 (p = 0.020) and week 3 (p = 0.041).

Conclusions

Treatment with Kivia powder, an extract of kiwifruit containing Zyactinase™, for four weeks was well tolerated and more effective than placebo in gently enhancing bowel movement frequency and reducing abdominal pain and flatulence in subjects with occasional constipation.

Trial registration

ISRCTN: ISRCTN49036618

【 授权许可】

   
2013 Udani and Bloom; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]McCrea GL, Miaskowski C, Stotts NA, Macera L, Varma MG: A review of the literature on gender and Age differences in the prevalence and characteristics of constipation in north america. J Pain Symptom Manage 2009, 37(4):737-745.
• [2]Higgins PD, Johanson JF: Epidemiology of constipation in north america: a systematic review. Am J Gastroenterol 2004, 99(4):750-759.
• [3]Bouras EP, Tangalos EG: Chronic constipation in the elderly. Gastroenterol Clin North Am 2009, 38(3):463-480.
• [4]Shaheen NJ, Hansen RA, Morgan DR, Gangarosa LM, Ringel Y, Thiny MT, Russo MW, Sandler RS: The burden of gastrointestinal and liver diseases, 2006. Am J Gastroenterol 2006, 101(9):2128-2138.
• [5]Leung L, Riutta T, Kotecha J, Rosser W: Chronic constipation: an evidence-based review. J Am Board Fam Med 2011, 24(4):436-451.
• [6]Odes HS, Madar Z: A double-blind trial of a celandin, aloevera and psyllium laxative preparation in adult patients with constipation. Digestion 1991, 49(2):65-71.
• [7]McRorie JW, Daggy BP, Morel JG, Diersing PS, Miner PB, Robinson M: Psyllium is superior to docusate sodium for treatment of chronic constipation. Aliment Pharmacol Ther 1998, 12(5):491-497.
• [8]Koebnick C, Wagner I, Leitzmann P, Stern U, Zunft HJ: Probiotic beverage containing lactobacillus casei shirota improves gastrointestinal symptoms in patients with chronic constipation. Can J Gastroenterol 2003, 17(11):655-659.
• [9]Uebaba K, Urata T, Suzuki N, Arai T, Strong JM, Oono S, Hayashi H: Mild laxative and QOL-improving effects of kiwi fruit extract in the elderly. Jpn J Complement Altern Med 2009, 6(1):97-103.
• [10]Rush E, Patel M, Plank LD, Ferguson LR: Kiwifruit promotes laxation in the elderly. Asia Pacific J Clin Nutr 2002, 11(2):164-168.
• [11]Chan A, Leung G, Tong T, Wong N: Increasing dietary fiber intake in terms of kiwifruit improves constipation in Chinese patients. World J Gastroenterol 2007, 13(35):4771-4775.
• [12]Harris PJ, Ferguson LR: Dietary fibre: its composition and role in protection against colorectal cancer. Mutation Res 1993, 290:97-110.
• [13]Matharu K, Weir I: Vital food technical dossier. Vital Foods Processors
• [14]Thomas L, Low C, Webb C, Ramos E, Panarese A, Clarke R: Naturally occurring fruit juices dislodge meat bolus obstruction in vitro. Clin Otolaryngol Allied Sci 2004, 29(6):694-697.
• [15]Kaur L, Rutherfurd SM, Moughan PJ, Drummond L, Boland MJ: Actinidin enhances gastric protein digestion as assessed using an in vitro gastric digestion model. J Agric Food Chem 2010, 58(8):5068-5073.
• [16]Kaur L, Rutherfurd SM, Moughan PJ, Drummond L, Boland MJ: Actinidin enhances protein digestion in the small intestine as assessed using an in vitro digestion model. J Agric Food Chem 2010, 58(8):5074-5080.
• [17]Schroder R, Nicolas P, Vincent SJ, Fischer M, Reymond S, Redgwell RJ: Purification and characterisation of a galactoglucomannan from kiwifruit (actinidia deliciosa). Carbohydr Res 2001, 331(3):291-306.
• [18]Pastorello EA, Conti A, Pravettoni V, Farioli L, Rivolta F, Ansaloni R, Ispano M, Incorvaia C, Giuffrida MG, Ortolani C: Identification of actinidin as the major allergen of kiwi fruit. J Allergy Clin Immunol 1998, 101:531-7.